Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation

• Main Authors: Hyungsoo Kim, Dennie T. Frederick, Mitchell P. Levesque, Zachary A. Cooper, Yongmei Feng, Clemens Krepler, Laurence Brill, Yardena Samuels, Nicholas K. Hayward, Ally Perlina, Adriano Piris, Tongwu Zhang, Ruth Halaban, Meenhard M. Herlyn, Kevin M. Brown, Jennifer A. Wargo, Reinhard Dummer, Keith T. Flaherty, Ze’ev A. Ronai
• Format: Article
• Language: English
• Published: Elsevier 2015-06-01
• Series: Cell Reports
• Online Access: http://www.sciencedirect.com/science/article/pii/S2211124715004660

Despite the remarkable clinical response of melanoma harboring BRAF mutations to BRAF inhibitors (BRAFi), most tumors become resistant. Here, we identified the downregulation of the ubiquitin ligase RNF125 in BRAFi-resistant melanomas and demonstrated its role in intrinsic and adaptive resistance to BRAFi in cultures as well as its association with resistance in tumor specimens. Sox10/MITF expression correlated with and contributed to RNF125 transcription. Reduced RNF125 was associated with elevated expression of receptor tyrosine kinases (RTKs), including EGFR. Notably, RNF125 altered RTK expression through JAK1, which we identified as an RNF125 substrate. RNF125 bound to and ubiquitinated JAK1, prompting its degradation and suppressing RTK expression. Inhibition of JAK1 and EGFR signaling overcame BRAFi resistance in melanoma with reduced RNF125 expression, as shown in culture and in in vivo xenografts. Our findings suggest that combination therapies targeting both JAK1 and EGFR could be effective against BRAFi-resistant tumors with de novo low RNF125 expression.